Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of JNJ-81201887 in Geographic Atrophy Secondary to AMD
NCT06635148Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2024
- Primary completion
- Aug 2029
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 18
01
Overview
A Phase 3 trial of JNJ-81201887 in geographic atrophy (GA), age-related macular degeneration (AMD), sponsored by Janssen Pharmaceutical. Started Sep 2024; status: recruiting.
02
Drugs
JNJ-81201887
03
Conditions
geographic atrophy (GA)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT06635148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06635148.